EW
Edwards Lifesciences Corp
NYSE · Healthcare · Medical - Devices · US
$87.22
+0.72%Year over year
Reported trailing growth
- Revenue
- +14.6%
- EBITDA
- -11.2%
- EBIT
- +22.9%
- EPS
- -75.0%
- Free cash flow
- +135.8%
- Operating cash flow
- +116.4%
Forward estimates
Based on analyst estimates
- Revenue
- +11.2%
- EBITDA
- +42.1%
- EPS
- +87.0%
Three-year CAGR
- Revenue
- +4.1%
- EBITDA
- -9.6%
- EBIT
- -1.3%
- Net income
- -11.0%
- EPS
- -9.2%
- Free cash flow
- +11.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026